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CD229 (Ly9) Lymphocyte Cell Surface Receptor Interacts
Homophilically through Its N-Terminal Domain and
Relocalizes to the Immunological Synapse1
Xavier Romero,2* Nuria Zapater,2* Marı´a Calvo,† Susana G. Kalko,‡
Miguel Angel de la Fuente,* Victoria Tovar,* Charlotte Ockeloen,§ Pilar Pizcueta,* and
Pablo Engel3*
CD229 is a member of the CD150 family of the Ig superfamily expressed on T and B cells. Receptors of this family regulate
cytokine production and cytotoxicity of lymphocytes and NK cells. The cytoplasmic tail of CD229 binds to SAP, a protein that is
defective in X-linked lymphoproliferative syndrome. To identify the CD229 ligand, we generated a soluble Ig fusion protein
containing the two N-terminal extracellular domains of human CD229 (CD229-Ig). CD229-Ig bound to CD229-transfected cells,
whereas no binding was detected on cells expressing other CD150 family receptors, showing that CD229 binds homophilically.
Both human and mouse CD229 interacted with itself. Domain deletion mutants showed that the N-terminal Ig-domain mediates
homophilic adhesion. CD229-CD229 binding was severely compromised when the charged amino acids E27 and E29 on the
predicted B-C loop and R89 on the F-G loop of the N-terminal domain were mutated to alanine. In contrast, one mutation, R44A,
enhanced the homophilic interaction. Confocal microscopy image analysis revealed relocalization of CD229 to the contact area of
T and B cells during Ag-dependent immune synapse formation. Thus, CD229 is its own ligand and participates in the immuno-
logical synapse. The Journal of Immunology, 2005, 174: 7033–7042.
I nteractions between cell surface molecules, expressed by var-ious hemopoietic cell types, regulate immune responses. Aconsiderable number of these cell surface molecules belong
to the Ig superfamily (IgSF),4 which has evolved as a large but
diverse group of genes encoding proteins involved in bimolecular
recognition (1). The extracellular domains of IgSF proteins are
involved in multiple specific cell-cell interactions, both homophilic
and heterophilic. These interactions trigger intracellular signals
that determine numerous cellular functions including activation,
differentiation, proliferation, and acquisition of effector function
and/or tolerance induction (2). Even though most of these cell
surface receptors lack intrinsic enzymatic activity, they recruit in-
tracellular kinases, phosphatases, and adapter proteins in response
to engagement by their ligands or counterreceptors (3).
CD229, previously known as Ly9, is expressed in T and B lym-
phocytes, and thymocytes (4–7). It belongs to the CD150 family,
a group of structurally related leukocyte cell surface receptors of
the IgSF. Members of this family of immunoreceptors are involved
in the functional regulation of several immune cell types, including
helper and cytotoxic T lymphocytes, NK cells, and macrophages
(8–11). The CD150 family includes a number of cell surface re-
ceptors, CD229, CD48, CD84, CD150 (SLAM), CD244 (2B4),
NTB-A (Ly108), CS1 (novel Ly9; CRACC), CD84-H1, and
BLAME (BCM-like) (9). These molecules are type I transmem-
brane glycoproteins that contain a cytoplasmic tail, with the ex-
ception of CD48, which has a GPI anchor to the membrane. The
extracellular ectodomain of this group of proteins comprises N-
terminal V-set Ig domains lacking the canonical disulfide bond and
C-terminal C2-set Ig domains, which are characterized by similar
patterns of conserved cysteines. Although the extracellular do-
mains of CD2 and CD58 share some of these characteristics (12,
13), the homology between these two leukocyte receptors and
members of the CD150 family is low (15% identity) (14). Unlike
other members of the CD150 family, CD229 has four rather than
two extracellular Ig domains. Domains 1 and 3 are similar, as are
domains 2 and 4, suggesting that CD229 arose from a progenitor
with two Ig domains (5). The cytoplasmic domain of CD229, sim-
ilar to several members of the CD150 family, contains two copies
of the tyrosine-based motif (T-I/V-Y-x-x-V/I) (6). This unique mo-
tif is a docking site for SH2-binding phosphatases and the adapter
molecules SAP and EAT-2 (15, 16). It has recently been shown
that SAP is required for CD229 tyrosine phosphorylation in T
lymphocytes (17). The SH2D1A gene, which encodes SAP, is de-
leted or mutated in patients with X-linked lymphoproliferative dis-
ease (18, 19), an unusual immunodeficiency characterized by un-
controlled polyclonal expansion of both T and B cells after an
EBV infection, resulting in fatal mononucleosis. Some other clin-
ical manifestations of this disease include B cell lymphoma and
dysgammaglobulinemia (20). The lethal immunodeficiency ob-
served in X-linked lymphoproliferative disease patients points to a
critical role of the CD150 family of SAP-binding cell surface re-
ceptors in the regulation of the immune system (9). Recently,
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CD229 was shown to associate with the -chain of the AP-2 adap-
tor complex, which links transmembrane molecules with clathrin-
coated pits (21). TCR and CD229 coligation enhances CD229 en-
docytosis, suggesting that Ag receptor signaling regulates the
availability of CD229 at the plasma membrane. CD229 is the only
member of the CD150 family that binds to the AP-2 complex.
Through their extracellular domain, the CD150 immunoreceptors
interact with specific ligands. One common feature of this subset of
molecules is that they interact with members of the same family;
CD150, CD84, CS1, and NTB-A all participate in homophilic inter-
actions, whereas CD244 (2B4) is a receptor for CD48 (22–26). The
counterreceptor of CD229 is currently unknown.
During Ag recognition, T cells undergo substantial membrane
and cytoskeletal rearrangements that lead to the formation of the
immunological synapse (27, 28). The TCR, accessory cell surface
molecules, and intracellular signaling molecules that are incorpo-
rated into and around the contact zone between T cells and APCs
all contribute to the modulation of the functional state of the syn-
apse. The immunological synapse appears to be essential to estab-
lish the persistent signaling necessary for full activation and is
implicated in the control of the quality and extent of biological T
cell responses. Recently, it has been reported that CD244 (2B4),
which is a member of the CD150 family, redistributes to the cen-
tral zone of the cytotoxic NK immune synapse (29). However, the
behavior of CD229 and other members of the family during im-
munological synapse formation remains to be elucidated.
Here we show that CD229 interacts homophilically through its
N-terminal V-like domain and identify the amino acid residues
essential for binding. We also show that CD229 localizes to the
contact site between T cells and Ag-presenting B cells during Ag-
dependent immune synapse formation.
Materials and Methods
Cells and reagents
COS-7 cells, the lymphoblastoid B cell line Raji, and the murine myeloma
cell line NS-1 were obtained from the American Type Culture Collection.
The Armenian hamster kidney cell line was obtained in our laboratory by
transfecting a primary culture of kidney cells with SV40. The Jurkat-de-
rived human cell line V8 J77cl20 was kindly provided by A. Alcover
and has been described previously (30). Cell lines were cultured in com-
plete RPMI 1640 supplemented with 10% FCS, penicillin/streptomycin,
and L-glutamine (Life Technologies). The following mAbs were produced
in our laboratory: anti-human CD84 (clone CD84.1.21) (23), anti-human
CD229 (clones HLy9.1.84, HLy9.1.38, HLy9.1.25, HLy9.1.77) (6) and
anti-human CD150 (clone SLAM 4) (31). The anti-CD244 mAb (clone
69-IgG1) was generated by fusing myeloma cell line NS1 with the spleen
cells of a BALB/c mouse immunized three times with the human CD244-Ig
fusion protein (decribed bellow). The mAbs anti-murine CD229 (clone
Ly9ab3) and anti-murine CD84 (clone mCD84.7) were generated by fusing
NS1 with spleen cells obtained from Armenian hamsters that were immu-
nized three times with the Armenian hamster kidney cell line transiently
transfected with murine full-length Ly9 cDNA or the Ig fusion protein of
murine CD84 (mCD84-Ig), respectively. Hybridomas were subcloned at
least three times. mAbs were purified using the Affi-Gel Protein A MAPS
II kit (Bio-Rad) from concentrated supernatants obtained from the culture
of hybridomas in INTEGRA CL 1000 flasks (Integra Biosciences).
Anti-human CD48 mAb (clone 156.4H9) and LFA-1 (clone 68-5A5)
were a gift from R. Vilella (Hospital Clı´nic, Barcelona, Spain), and NTB-A
mAb (clone MA127) was a gift from A. Moretta (32). The following mAbs
were obtained from BD Pharmingen: anti-human CD3-FITC; CD45-FITC;
CD2-PE; CD58-PE; biotin anti-mouse Ig; and TNP. Biotin-conjugated
anti-human IgG, streptavidin-Cy3 and anti-mouse-Cy3 were purchased
from Jackson ImmunoResearch Laboratories and streptavidin-PE was from
Southern Biotechnology Associates. Anti-mouse IgG labeled with HRP
was obtained from Sigma-Aldrich.
Chimeric CD229 molecules and splice variants
Two human/mouse CD229 cDNAs chimeric molecules were produced.
Chimeric molecule hDI/II mDIII/IIV was made by joining the cDNA that
encodes domains I and II of human CD229 with domains III and IV of
murine CD229, whereas the chimeric molecule hDI/DIII/DIV mDII was
constructed using domains I, III, and IV of human CD229 and domain II
of murine CD229. The chimera hDI/II mDIII/IV was constructed with two
fragments generated by PCR. The first PCR product was generated using
human CD229 cDNA as template and the HLy9 wild-type (wt) forward
oligonucleotide (Table I) and overlapping reverse oligonucleotide 5-TCT
TCT GGA GGC TC/C TGG ATC TGT ACA GAA C-3. The second PCR
product was generated using the murine (C57BL/6) CD229 cDNA as tem-
plate and overlapping forward oligonucleotide 5-GTT CTG TAC AGA
TCC AG/G AGC CTC CAG AAG A-3 and reverse oligonucleotide 5-
TTC TCC AAA TCC TCA CCC CG-3. Each PCR product was used for
a recombinant PCR containing the primers HLy9 wt and reverse primer of
murine CD229.
Chimeric molecule hDI/DIII/DIV mDII was constructed using three
products generated by PCR. The first PCR product, corresponding to the
first domain of human CD229, was amplified using human CD229 cDNA
as template and HLy9 wt forward oligonucleotide (Table I) and overlap-
ping reverse oligonucleotide 5-GGC TTC TGG AGC TTC TCA TAG
ACG AAA AGG GTG-3. The second PCR product, corresponding to the
second domain of murine CD229, was generated using murine (C57BL/6)
CD229 cDNA as template and the overlapping forward oligonucleotide
5-CAC CCT GTT CGT CTA TGA GAA GCT CCA GAA GCC-3 and
overlapping reverse oligonucleotide 5-GTT CCT CCT CTG GAG GCT
CCT GTG CAG AAT TGC CA-3. The third PCR product was amplified
using human CD229 cDNA as template and the overlapping forward ol-
ogonucleotide 5-CTG GCA ATT CTG CAC AGG AGC CTC CAG AGG
A-3, and the HLy9 wt reverse oligonuclotide (Table I). PCR products
were used for a recombinant PCR to anneal overlapping ends. The human/
mouse chimeric molecules were cloned into pcDNA3.1/V5/His-TOPO ex-
pression vector (Invitrogen) fully sequenced and transfected in COS cells.
As control, murine CD229 full-length cDNA was transfected in COS cells
and tested with the anti-human CD229 mAbs to rule out possible cross-
reactivity of these mAbs with murine CD229.
A CD229 isoform that lacks the first Ig domain (CD229 DI) was iso-
lated from the thymus by RT-PCR and subcloned in PCIneo expression
vector. The reactivity of CD229 mAbs (HLy9.1.25, HLy9.1.38, HLy.1.77
and HLy9.1.84) with COS cells transfected with the chimeric molecules,
and the splicing variant CD229 DI cDNAs was analyzed using flow
cytometry.
Construction of the fusion proteins
The human CD229-Ig (CD229-Ig), human CD244-Ig (CD244-Ig), murine
CD84-Ig (mCD84-Ig), and murine CD229-Ig (mCD229-Ig) fusion proteins
Table I. CD229 primers for site-directed mutagenesis
Mutation Sense Primer (5–3) Antisense Primer (5–3)
HLy9wt gctagcatgagtcagctgcaaatattctct gcagcagctgcttttcctttcaggtgaa
D25A ctcagtagccacagagattg tcaatctctgtggctactga
E27A gtatacacagcgattgagaac gttctcaatcgctgtgtctac
E29A cacagagattgcgaacgtcat atgacgttcgcaatctctgtg
K37A gattggtcccgcaaatgctct agagcatttgcgggaccaatc
L40A caaaaatgctgctggctttcgc gcgaaagcagcagcatttttg
R44A tcgcagctcccaaagaaaatg cattttctttgggagctgcga
K46A cgtcccgcagaaaatgtaacc ggtttacattttctgcgggacg
E47A cgtcccaaagcaaatgtaacc ggttacatttgctttgggacg
R89A gcccagataaaccaagcgaatt aattcgcttggtttatctgggc
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containing the CD33 leader peptide and the Fc region of human IgG1 were
obtained by inserting the sequences corresponding to the first and second
extracellular Ig domains into the mammalian expression vector signal pIg-
Tail (R&D Systems). The oligonucleotides used were as follows: human
CD229 forward oligonucleotide, 5-AGG AAG ATC TAA AGG ACT
CAG CCC CAA CAG TGG T-3, and reverse oligonucleotide, 5-AGG
AAG ATC TAC TTA CCT GTT CTG GAG GCT CCT GGA TCT GTA
C-3; human CD244 forward oligonucleotide, 5-AGG GGG ATC CAT
GCC AGG GTT CAG CTG ACC A-3, and reverse oligonucleotide, 5-
ACC AGG ATC CAC TTA CCT GTG AAT TCC TGA TGG GCA TTC
TGA C- 3; murine CD84 forward oligonucleotide, 5-TCG AGG ATC
CAA AAG ATG CAG ACC CGG TGG T-3, and reverse oligonucleotide,
5-TAA CGG ATC CAC TTA CCT GTA TG AAG CTT GGA GTG TCT
G-3; murine CD229 forward oligonucleotide, 5-GTT CAG ATC TAA
AGG AAA CAC CTC CAA CAG TGA T-3, and reverse oligonucleotide,
5-GTC AAG ATC TAC TTA CCT GTT CTG GAG GCT CCT GTG
CAG AAT TGC CA-3. Human CD84-Ig was obtained in our laboratory
(23). The constructs corresponding the Ig fusion proteins were subcloned
in the expression vector pCI-neo (Promega) and NS-1 stable transfectants
were obtained by electroporation and selection with 1.2 mg/ml geneticin
(G418) (Life Technologies). Eight million cells were electroporated (280
V, 950 F) with 8 g of linearized DNA using the Gene Pulser II Appa-
ratus (Bio-Rad). The transfected cells were plated in flat-bottom 96-well
tissue culture plates (Corning) by limiting dilution, and clones producing
high amounts of fusion protein were cultured in INTEGRA CL 1000 flasks
(Integra Biosciences). The supernatants containing the fusion proteins were
purified as described for the mAbs.
Site-directed mutagenesis
Site-directed mutagenesis of single residues was performed using a set of
sense and antisense primers containing the appropriate mutation (Table I).
wt CD229 cDNA was used as template. The first PCR used either the sense
primer 5-AGT TCT GAA AAT AGA TCA TCA TGG-3 plus an anti-
sense primer containing the mismatched base or a sense primer that con-
tained the mismatched base plus the antisense primer 5-AGC TGC TTT
TCC TTT CAG GTG-3 to create two PCR products that overlapped
within the region spanned by the mutagenized sense and antisense primers.
The reactions were conducted as follows: 95°C for 5 min, followed by 35
cycles of 95°C for 30 s, 56°C for 30 s, 72°C for 2 min, with a final
extension period of 72°C for 6 min. Aliquots of 3 l of a 1/25 dilution of
each PCR product were used as templates for a recombinant PCR contain-
ing the primers of the full-length CD229. The conditions of the PCR were the
same as before. PCR products were cloned into the pcDNA3.1/V5/His-TOPO
expression vector (Invitrogen). After confirming mutated clones by automatic
sequencing, each cDNA mutant was transfected into COS-7 cells.
COS transfection
One million COS-7 cells were transiently transfected with 3 g of cDNA
corresponding to human CD229 or the CD229 mutants, CD229 chimeras,
CD229 splice variant (CD229 DI), CD84, CD150, CD244, CD48, CD2,
CD58, and NTB-A using 100 l of Nucleofector Solution V according to the
manufacturer’s protocol (AMAXA Biosystems). The cells were analyzed 24 h
after transfection either by flow cytometry or by immunocytochemistry.
Immunocytochemistry
Transiently transfected COS-7 cells were cultured on glass coverslips in
24-well tissue culture plates (Corning). After 48 h, cells were fixed with
4% paraformaldehyde at 4°C and then blocked with 3% BSA (Sigma-
Aldrich). Cells were labeled with HLy9.1.25, HLy9.1.38, and HLy9.1.77
mAbs and CD229-Ig fusion protein for 1 h at room temperature. After a
washing in PBS, samples were incubated with Cy3-conjugated anti-mouse
IgG or biotin-conjugated anti-human IgG (Jackson ImmunoResearch Lab-
oratories). Samples were washed twice in PBS and mounted in Fluoro-
mount-G (Southern Biotechnology). Fluorescence images were obtained
using a confocal spectral microscope (TCS SL; Leica).
Flow cytometry
Flow cytometry was conducted with transfected cells stained with anti-
human mAbs, followed by biotinylated anti-mouse  L chain, plus strepta-
vidin-PE (BD Pharmingen). Ig fusion protein staining was performed using
2 g of Ig fusion protein followed by incubation with biotin-conjugated
anti-human IgG (Jackson ImmunoResearch Laboratories) and then strepta-
vidin-PE. The stained cells were analyzed using a FACSCalibur (BD Bio-
sciences Immunocytometry Systems) equipped with CellQuest software.
Ten thousand cells were counted for each sample.
Molecular modeling of the CD229 N-terminal domain
We used the alignment mode of SWISS-MODEL, an automated modeling
process based on a user-defined target-template alignment (33). We ob-
tained a first model of 78 residues (corresponding to residues 13–90 of the
N-terminal domain of CD229) from the alignment between our target and
CD58 and a second model of 42 residues (corresponding to residues 63–
104 of the N-terminal domain of CD229) from the alignment between our
target and CD2. The final model presented here is 90 residues long and was
constructed using the three-dimensional alignment CE method with the
first and second models (34). Our final model shows the archetypical fold
of V Ig variable domains characterized by nine  strands forming two
antiparallel  sheets. The first  strand was not modeled.
Immunological synapse formation and immunofluorescence
microscopy
To distinguish B (Raji) from T (Jurkat V8 J77cl20) lymphocytes, Raji
cells were loaded with the fluorescent cell tracker chloromethyl derivative
of aminocoumarin (CMAC; 10 M) or 5-chloromethylfluorescein diac-
etate (3 M) (Molecular Probes). B cells were incubated for 20 min at
37°C with 2 g/ml staphylococcal enterotoxin (SEE) (Toxin Technology).
Jurkat cells were mixed with Raji cells (proportion, 1:1) and incubated for
15 min at 37°C. Cells were plated onto poly-L-lysine-coated slides (50
g/ml; Sigma), incubated for 20 min at 37°C, and fixed in 4% formalde-
hyde. For immunofluorescence assays, samples were blocked with PBS
containing 2% BSA, and Fc receptors were blocked with 15% of heat-
inactivated rabbit serum (Life Technologies). Cells were labeled with
mAbs followed by Cy3-conjugated goat anti-mouse (Jackson ImmunoRe-
search Laboratories). For visualization of immunological synapse forma-
tion, confocal images were acquired using a Leica TCS SL laser scanning
confocal spectral microscope (Leica Microsystems Heidelberg) with argon
and helium-neon lasers attached to a Leica DMIRE2 inverted microscope.
All images were obtained using a 63 oil immersion objective lens (NA
1.32) equipped with phase contrast optics. Due to the small size of the cells,
electronic zoom was necessary for higher magnification and better image res-
olution. The images of CMAC-labeled Raji cells were obtained using a mer-
cury lamp HBO 50W UV filter as light source after each acquisition of fluo-
rescence confocal and phase contrast images. Image assembly and treatment
were performed using the Leica Confocal Image Processing Software.
B cell line Raji was negatively selected for CD229 expression using
three sequential pannings. Briefly, polystyrene bacteriological petri dishes
(100  15 mm) were coated overnight at 4°C with of HLy9.1.84 mAb at
10 g/ml in PBS. The dishes were washed twice with PBS and blocked
with PBS containing 0.2% BSA (Sigma-Aldrich) for 1 h at room temper-
ature. The dishes were washed once with PBS, and then 10 106 Raji cells
were added and incubated for 40 min at 4°C. Nonadherent Raji cells were
collected. This procedure was repeated three times. The collected Raji cells
expressed almost undetectable CD229 levels (Raji CD229). These cells
were used to perform immunological synapse formation studies. Contacts
of Jurkat cells with Raji CD229 cells that expressed detectable levels of
CD229 in the confocal images were excluded from the analysis.
Statistical analysis
The Sigma Stat statistical package (Jandel Scientific Software) was used in
the analysis of the results. All results are reported as mean  SEM. Sta-
tistical significance was set at p  0.05. ANOVA and Student’s t test with
Bonferroni’s correction were used.
Results
CD229 interacts homophilically
To identify the ligand of CD229, we assessed binding of a
CD229-Ig fusion protein to COS-7 cells transiently transfected
with CD2, CD58, or members of the CD150 family. Binding was
detected only with CD229. CD2-, CD58-, CD84-, CD150-, CD48-,
CD244-, and NTB-A transfected cells were all negative (Fig. 1).
The specific binding of CD244-Ig to CD48 was used as a positive
control (Fig. 1). CD229 homophilic binding was also observed in
mice (Fig. 2A). Moreover, the CD229-CD229 homophilic interac-
tion is not species restricted because human CD229 can bind to
mouse CD229 and vice versa (Fig. 2B). This is in contrast to CD84
homophilic binding, which is species restricted, because human
CD84 does not bind to murine CD84, although murine CD84 can
bind to itself (Fig. 2A).
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FIGURE 1. CD229 exhibits homotypic bind-
ing. COS-7 cells transfected with human
CD229, CD2, CD48, NTB-A, CD58, CD244,
CD84, and CD150 cDNA were labeled with
CD229-Ig or CD244-Ig fusion proteins. Protein
expression was detected using specific Abs (left
column). Transfected cells were assayed for
binding of CD229-Ig or CD244-Ig (middle and
right columns). Immunostaining controls: iso-
type controls (left column) and Ctl-Ig (murine
CD84-Ig; middle and right columns) are repre-
sented with dotted lines. The percentage of pos-
itive cells is indicated in each histogram.
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Domain mapping of CD229 mAbs
To identify the Ig-like domains that are involved in the homophilic
interaction of CD229, domain mapping was performed for the four
mAbs previously produced by our laboratory (6). mAb binding to
COS cells transfected with CD229 human/mouse chimeras indi-
cated that HLy9.1.25, HLy9.1.38, and HLy9.1.77 were directed
against Ig domain I, whereas HLy9.1.84 was reactive with Ig do-
main II (Table II). Moreover, only mAb HLy9.1.84 was able to
bind with COS cells transfected with a CD229 isoform that lacks
the first Ig domain (CD229 DI), further demonstrating that this
mAb recognizes the second Ig domain. Cross-blocking studies
showed that the mAbs recognized three epitopes: HLy9.1.25 and
HLy9.1.38 recognize epitope A; HLy9.1.77 recognize epitope B;
and HLy9.1.84 recognize epitope C (Table III).
The N-terminal domain of CD229 mediates homophilic
interaction
CD229-Ig binding was tested with CD229 DI. This isoform was
expressed on the cell surface of transfected COS cells as shown by
positive staining with mAb HLy9.1.84. Deletion of the first V do-
main completely abolished binding of CD229-Ig, indicating that
the direct and exclusive interaction between two opposing V do-
mains is crucial for the homophilic CD229 interaction (Fig. 3).
Furthermore, monovalent Fab of mAb HLy9.1.77, which maps
to the first Ig domains and reacts with epitope B, were able to
partially block (60%) the binding of CD229-Fc to wt CD229-trans-
fected cells. In contrast, Abs recognizing epitope A, located in
domain I, and mAb recognizing epitope C, located within domain
Table III. Ability of test mAbs to block the binding of labeled mAbs to
CD229–300.19 cellsa
Test mAbs
Labeled mAbs
HLy9.1.25 HLy9.1.38 HLy9.1.77 HLy9.1.84
HLy9.1.25    
HLy9.1.38    
HLy9.1.77    
HLy9.1.84    
a Symbols represent the relative ability of test mAbs to block the binding of the
indicated labeled mAbs to CD229–300.19 cells. Symbols indicate the percentage de-
crease in the number of fluorescence-positive cells: , 20% of positive cells; , 20–
50% of positive cells; , 50–80% of positive cells; , 80% of positive cells.
FIGURE 2. Human and murine CD229 re-
ceptors interact homophilically. A, COS-7
cells transfected with full-length murine CD84
(upper panel) or full-length human CD84
(lower panel) were labeled with specific Abs
mCD84.7 and CD84.1.21 (left column). Hu-
man CD84-Ig (hCD84-Ig) or murine CD84-Ig
(mCD84-Ig) binding was assayed (middle and
right columns). B, COS-7 cells transfected
with full-length murine CD229 (upper panel)
or the full-length human CD229 (lower panel)
were labeled with specific Abs Ly9ab3 and
HLy9.1.25 (left column). Human CD229-Ig
(hCD229-Ig) or murine CD229-Ig (mCD229-
Ig) binding was assayed (middle and right col-
umns). Immunostaining controls: isotype con-
trols (left column) and Ctl-Ig (CD244-Ig;
middle and right columns) are represented
with dotted lines. The percentage of positive
cells is indicated in each histogram.
Table II. Mapping the interaction domain of CD229 mAbsa
mAbs
CD229 hDI/DII
mDIII/DIV
CD229 hDI/
DIII/DIV mDII
CD229
DI
mAb Interaction
Domainb
HLy9.1.25    DI
HLy9.1.38    DI
HLy9.1.77    DI
HLy9.1.84    DII
a COS cells were transiently transfected with chimeric human (h)/mouse (m) con-
structs or the isoform lacking the first V-like Ig domain (CD229 DI) described in
Materials and Methods. CD229 mAbs were assayed by flow cytometry: , Detection
of protein expression, , nondetection of protein expression.
b Domain recognized by the mAb.
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II, did not significantly block CD229-Ig binding to CD229-trans-
fected COS cells (data not shown). These data demonstrate that the
first Ig domain mediates homophilic binding of CD229.
Identification of the key amino acid residues on the GFCCC	
face involved in CD229 homophilic interaction
Surface-exposed charged amino acids have been proposed to be
involved in the intermolecular interaction of the N-terminal Ig do-
mains of CD2 and its counterreceptor CD58 (35, 36). To identify
key amino acid residues of CD229 that contribute to homophilic
binding, a number of point mutations were generated by site-di-
rected mutagenesis. Several charged amino acids that are
conserved between human and murine CD229, located at the
GFCCC	 face of the N-terminal Ig domain, were mutated to ala-
nine. Binding of the CD229-Ig fusion protein was tested in COS
cells transfected with wt and mutated CD229. COS cells express-
ing mutant CD229 molecules at levels comparable with wt were
analyzed by flow cytometry and immunocytochemistry (Table IV
and Fig. 4). To assess whether any of these mutations resulted in
alterations of their tertiary structure that could affect their adhesion
to a CD229 ligand, we tested their immunoreactivity with three
mAbs, HLy9.1.25, HLy9.1.38, and HLy9.1.77, that recognize
epitopes located within the first Ig-like domain. All of the mutants
tested reacted similarly with these mAbs, suggesting no significant
alteration of the general tertiary structure (Fig. 4B). Our results
show that mutation of E27 and E29 on the predicted B-C loop and
R89 on the F-G loop of the N-terminal domain all cause a disrup-
tion of the binding by 80%, whereas the rest of the mutants had
no significant effect on the binding activity of CD229 (Table IV
and Fig. 4A). Surprisingly, one mutation, R44A, caused a signifi-
cant increase in binding to CD229-Ig (Table IV and Fig. 4).
CD229 redistributes to the contact area of T-B cell conjugates
in an Ag-dependent manner
Here we used confocal microscopy to examine the localization of
CD229 during Ag-dependent immune synapse formation. Supe-
rantigen activation of V8 Jurkat cells has been described to
trigger molecular polarization and segregation, forming a canoni-
cal immunological synapse (27). Jurkat T cells activated with the
bacterial superantigen SEE-pulsed Raji cells formed immunolog-
ical synapses similar to those described previously in mouse T
cells activated with peptide Ag-bearing B cells. Both Jurkat and
Raji cells expressed comparable levels of CD229. CD229 moved
to the interface of the T-B cell conjugate after Ag triggering (Fig.
5B). CD229 was re-localized in 13.2% of the T-B cell conjugates
analyzed in the absence of SEE. However, after incubation with
SEE, the number of conjugates in which CD229 relocalized to the
T-B cell contact area increased to a 38.0%, similar to the relocal-
ization levels of CD3 (Fig. 5 and Table V). In contrast, CD45 was
homogeneously distributed around the cell surface (Fig. 5 and Ta-
ble V). The relocalization of CD229 was observed on both the
Jurkat T cell and the Raji APC (Table VI). Moreover, the relocal-
ization of CD229 was significantly affected by the presence of
CD229 on APCs, because we observed that CD229 relocalization
was significantly reduced when CD229 was not present on APCs
in both the presence and the absence of SEE. In contrast, no sig-
nificant differences in the relocalization of CD3 were observed
(Fig. 6). To further analyze the localization of CD229 at the im-
munological synapse, colocalization studies were performed. We
observed that the compact clusters of CD3 were embedded in large
accumulations of CD229, similar to those observed with the inte-
grin LFA-1 (Fig. 5A). Together, these data show that CD229 lo-
calizes to the immunological synapse.
Discussion
In this study, we have demonstrated that CD229 is a self-ligand,
interacting through its N-terminal V-like domain, in which we
have identified three residues critical for the homophilic interac-
tion. We observed that a soluble CD229-Fc fusion protein binds to
CD229-transfected cells, but not to cells transfected with the
cDNA of other members of the CD150 family or the related cell
surface molecules CD2 and CD58. Our data are consistent with the
observation that the only known ligands of the CD150 family of
cell surface receptors are other members of the same family. With
the exception of CD48, which binds to CD244, ligand interactions
within this family have been shown to be homophilic (CD84-
CD84, CD150-CD150, CS1-CS1, and NTB-A-NTB-A) (9, 25,
26). Here we have shown that both human and murine CD229 can
FIGURE 3. Homophilic binding of CD229 is mediated by the first extra-
cellular domain. COS-7 cells transiently transfected with cDNA encoding full-
length CD229 (upper panel) or the thymus CD229 isoform that lacks the first
Ig domain (CD229 D1), which contains DII/DIII and DIV (lower panel),
were stained with HLy9.1.25 or HLy9.1.84 (right column). CD229-Ig binding
(left column). Immunostaining controls: isotype controls (left column) and
Ctl-Ig (murine CD84-Ig; right column) are represented with dotted lines.
Table IV. Site-directed mutagenesis dissection of the homophilic
adhesion
CD229a
Location on
First Ig-like
Domainb
Relative CD229
Expressionc % Bindingd
wt 1.0 100
D25A BC loop 1.7 96
E27A BC loop 0.9 21
E29A BC loop 1.5 4
K37A CC loop 1.1 73
R44A CC loop 1.47 204
K46A C 0.7 51
E47A C 0.99 69
R89A FG loop 0.95 0
a COS cells transiently transfected with wt CD229 and mutant CD229 cDNAs.
b Strand assignment based on the modeling of CD229 described in Materials and
Methods.
c Expression of wt and mutant CD229 proteins labeled with HLy91.25 mAb were
measured by flow cytometry. Fluorescence intensities of wild-type or mutant CD229
vs wt CD229 are shown.
d Positive cells of wt and mutant CD229 proteins assayed with CD229-Ig were
measured by flow cytometry. Values are percent of positive cells of wt or mutant
CD229 vs wt CD229.
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bind to itself, indicating that the homophilic interaction of this
molecule occurs in different species. Moreover, the CD229-CD229
homophilic interaction is not species restricted, because human
CD229 also bound to murine CD229 and vice versa. This is in
contrast to our results with CD84 and to previous reports for other
members of the CD150 family where their interaction has been
shown to be species specific (23, 37). These data indicate that
residues involved in the homophilic interaction of CD229 may be
preserved between these two species.
Our structure-function analysis, using domain deletion mutants,
revealed that the homophilic interaction of CD229 is mediated by
the membrane distal N-terminal Ig domain. If additional Ig do-
mains were directly involved in this interaction, cells expressing a
CD229 that only lacks the N-terminal domain would be expected
to display a residual capacity to bind to CD229-Fc. However, sol-
uble ligand binding was completely abolished upon deletion of the
N-terminal V domain. Moreover, single amino acid point mutation
of residues located in the first Ig-like domain abolished the
CD229-CD229 interaction. N-terminal domains are generally im-
portant for the interaction of cell-adhesion molecules that belong
to the IgSF (38).
When homology can be demonstrated with well-characterized
proteins, many properties of the three-dimensional structure can be
predicted. The model building analysis of the N-terminal domain
of CD229 described here used the known structure of CD2 and
CD58 as a guide (35). The basic structure of the V-like N-terminal
domain of CD229 is a predicted tertiary fold of a stacked pair of
-pleated sheets. There are 9  strands, with strands A, B, E, and
D lying in one sheet and strands C, C, C	, F, and G lying anti-
parallel in the other (Fig. 7). Site-directed mutagenesis in CD2 and
CD58 has shown that charged residues located on the GFCCC	
face are critical for their interaction. The structural analysis of the
ligand-binding domains of CD2 and CD58 confirmed that the
binding is dominated by electrostatic contacts between binding
surfaces exhibiting considerable electrostatic complementarity.
Our results show that exposed residues on the GFCCC	 face of the
N-terminal domain also play a crucial role in homophilic interac-
tion of CD229. Single mutations of the negatively charged residues
E27 and E29 located in the predicted B-C loop, and the positively
charged residue R89 on the F-G loop, abolished the CD229-
CD229 interaction (Fig. 6). On the basis of mAb binding profiles,
the presence of gross structural perturbation or misfolding, as a
consequence of specific mutations was highly unlikely (Fig. 4B).
Thus, we speculate that the negatively charged residues (E27 and
E29) may interact with the positively charged residue (R89) in the
counterreceptor interacting interface between the N-terminal ad-
hesion domains of CD229. However, a crystal structure of CD229
binding to itself will be needed to confirm the actual way in which
these residues interact at the molecular level.
FIGURE 4. Identification of residues involved in ho-
mophilic interaction of CD229. A, COS-7 cells tran-
siently transfected with full-length CD229, E29A, or
R44A cDNA were stained with HLy9.1.25 mAb fol-
lowed by Cy3-conjugated anti-mouse Ig (upper panel).
The transfected cells were assayed with CD229-Ig fol-
lowed by biotinylated anti-human Fc Ab and avidin-Cy3
(lower panel). B, COS-7 cells transiently transfected
with full-length CD229, E27A, E29A, and R89A cDNAs
were stained with HLy9.1.25, HLy9.1.38, and HLy9.1.77
mAbs followed by biotinylated anti-  and streptavidin-PE.
Mean fluorescence intensities are shown.
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As suggested for CD2 and CD58, we hypothesize that CD229
molecules expressed on the surface of adjacent cells establish
head-to-head contacts. Of interest in this context is the observation
that dynamic binding between CD2 and CD58 counterreceptors on
opposing cells optimizes immune recognition through stabilization
of T cell and APC cell contact (35).
Surprisingly, mutation of residue R44 located in the CC	 loop
enhanced the binding of CD229 to itself, a phenomenon that has
been reported for other ligand-receptor pairs (39). This observation
may aid the design of fusion proteins or small peptides that could
be used to alter CD229 function in a therapeutic context.
Binding of the CD229-Ig could be observed only in transfected
cells overexpressing CD229, indicating that its affinity for itself is
weak. Nevertheless, CD229 binding is very specific, because it
bonds only to itself and not to any other member of the CD150
family. Low affinity interactions are a common feature of ho-
mophilic receptors of the Ig superfamily including CD150 (Kd 200
M). These interactions are characterized by remarkably fast on/
off rates that foster rapid and extensive exchanges between part-
ners on opposing cell surfaces. This is thought to allow cells to
rapidly form and break contacts, conferring plasticity at the cell-
cell contact areas or enabling the rapid surveillance of target mem-
branes (38, 40). Whereas the affinity of adhesion molecules often
Table V. Frequency of relocalization at the Raji-Jurkat ISa
Conjugates  SEE  SEE
CD3 1.1  1.1 47.4  7.2
CD45 8  2.8 9.1  0.4
CD229 13.2  1.0 38.0  1.8
a Quantification (%) of cell conjugates in which CD3, CD45, and CD229 were
relocalized at the T cell-APC contact area in the presence or absence of SEE. At least
100 conjugates from three independent experiments were analyzed. Results corre-
spond to the arithmetic mean  SD.
Table VI. Fold induction of fluorescence intensity at the ISa
CD229 (n 
 10) CD3 (n 
 5) CD45 (n 
 5)
IS vs T cell 4.2  2.0 13.1  4.6 0.9  0.2
IS vs APC 6.4  3.0 0.9  0.3
a Fluorescence intensity in the IS with respect to the rest of the T cell or APC
membrane fluorescence. n is the number of T cell-APC contacts analyzed from two
different experiments. Values are arithmetic means  SD. IS, Immune synapse.
FIGURE 5. CD229 localizes to the immune synapse.
A, Jurkat-Raji conjugates incubated for 10 min in the
presence or absence of SEE were allowed to adhere to
poly-L-lysine, fixed, and stained (red) for CD3, CD45,
LFA-1, and CD229. Phase contrast images merged with
green fluorescence from 5-chloromethylfluorescein di-
acetate-loaded Raji cells are shown. B, Jurkat-Raji con-
jugates incubated for 10 min in the presence of SEE and
double-stained for CD229 (red) and CD3 or CD45
(green). Phase contrast images merged with blue fluo-
rescence from CMAC-loaded Raji cells are shown.
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reflects a specific conformation of the extracellular binding do-
main, avidity modulation involves changes in the cellular distri-
bution, which leads to clusters of molecules and thereby specifi-
cally increases the number of available receptors at the site of
cell-cell interaction. This avidity can be further enhanced by the
participation of other adhesion molecules at the contact site, such
as the integrins (41). Thus, the lateral receptor mobility and accu-
mulation of multiple interface bonds will be required for the de-
velopment of appreciable adhesion.
To explore the functional relevance of CD229 homophilic bind-
ing, we analyzed its localization during immunological synapse
formation. Immune receptors and components of their signaling
cascades are spatially organized, and this spatial organization plays
a central role in the initiation and regulation of signaling (42). The
synapse is established and maintained to a large extent by the
interaction of glycoproteins expressed on the surface of adjacent
cells. Homophilic interactions of cell surface proteins typically re-
sult in their accumulation at sites of cell-cell contact. These mol-
ecules not only function as adhesion molecules but also translate
biochemical information. By doing so, they regulate the initiation
and prolongation of signaling triggered by ligand engagement of
the immune cell signaling receptors. The ability to segregate re-
ceptors provides a mechanism for the compartmentalization of sig-
naling components within the membrane, concentrating certain
components in the contact area and excluding others with negative
regulatory activity. Our results show that CD229 redistributes to
the contact area established between T cells and enterotoxin E
(SEE)-pulsed Ag-presenting B cells. The redistribution could be
observed in both the T and the B cell. Moreover, the presence of
CD229 on the B cell affected the relocalization of CD229 on the T
cell, indicating a role of CD229 homophilic interaction in its cel-
lular distribution (Fig. 6). However, CD229 homophilic interaction
was not required for CD3 relocalization to the immunological syn-
apse. Interestingly, the accumulation of CD229 was more evident
at the periphery of the contact region, surrounding the compact
clusters of CD3 (Fig. 5B). The molecular segregation of CD229
may be explained by the four-Ig domain structure of this cell sur-
face molecule. It has been observed that cell surface molecules of
the Ig superfamily that are present in the central synapse contain
just two Ig domains and that this may be important to ensure the
right distance for interactions between two cells. This is also the
case for the CD150 family member CD244 (2B4) (29). Consistent
with this notion, the interaction of CD2 with an elongated form of
CD48 significantly inhibits immune recognition (43). Recent stud-
ies in our laboratory indicate that CD229 inhibits rather than in-
duce T cell activation and cytokine production (44). Thus, we hy-
pothesize that CD229 is excluded from the central synapse to
prevent it from delivering negative signals. More studies including
dynamic redistribution analysis of CD229 will be required to elu-
cidate its contribution to the modulation of the functional state of
the immunological synapse.
FIGURE 6. CD229 relocalization
is affected by the presence of CD229
on APCs. Quantification of CD229 and
CD3 relocalization to the T-B contact
area of Jurkat-Raji or Jurkat-Raji
CD229 conjugates in the presence or
absence of SEE. More than 100 con-
tacts were analyzed in three indepen-
dent experiments. Histograms repre-
sent the arithmetic mean SD. , p
0.05 compared with Jurkat-Raji with
Jurkat-Raji CD229 conjugates not
treated with SEE. , p  0.05 com-
pared with Jurkat-Raji with Jurkat-Raji
CD229 conjugates treated with SEE.
FIGURE 7. Molecular model of the N-terminal IgV set domain of human
CD229. Ribbon diagram of the N-terminal domain of CD229 showing the
predicted homophilic interface. The  strands GFCCC	 are labeled according
to the standard convention. The face GFCCC	 is gold, and the ABED face is
gray. The mutated amino acids that strongly modify the interaction are indi-
cated on the model according to the one-letter amino acid codes. Substituted
amino acids that abolish adhesion are labeled in white, whereas residue 44,
which strongly enhances adhesion, is labeled in light blue. Negatively changed
atoms are labeled in red, and positively charged atoms are labeled in blue.
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Immunological synapse occurring during cognate interactions
between B and helper T cells, within the B cell follicles of sec-
ondary lymphoid organs, are required for humoral immune re-
sponses to many Ags (45). Expression of SAP by CD4 T cells is
essential for T cells to provide B cell help and establish long term
humoral immunity (46). The fact that CD229 is a SAP-associated
homophilic receptor expressed on both T and B cells and that it
localizes at the immune synapse suggests that this molecule has a
role in the regulation of T-B interactions. Further evidence sup-
porting the importance of CD229 in regulating T cell help for B
cells is the recent finding that CD229 is preferentially expressed by
effector T follicular helper cells (47).
The identification of CD229 as a homophilic receptor and char-
acterization of the binding site is an important step in advancing
our understanding of how this interaction can regulate the immune
response.
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